PEPDURA
Transforming Natural Peptides into Powerful Medicines
Pepdura develops stabilized peptide therapeutics for pain, inflammatory, and autoimmune diseases, built on over a decade of research at the Medical University of Vienna and universities in Austria and Australia.
​
Extensive experience in peptide drug design:
The Gruber Lab and its academic partners have generated new, proprietary technology to stabilize fragile natural regulatory peptides, transforming them into viable drug candidates with significant therapeutic potential.
Pepdura’s management has experience from stable peptide T20K, from laboratory to clinical phase 1.
Our Technology
Portfolio of non-addicitive drug candidates for pain
Peptide drug candidates targeting the kappa opioid receptor (KOR) offer a novel, non-addictive approach to pain management. These candidates show high receptor selectivity, exceptional stability in serum, and minimal risk for penetrating the central nervous system—greatly reducing the risk of side effects such as dysphoria and addiction.
​
​
"We’re transforming nature’s molecules into tomorrow’s medicines — safely, precisely, and powerfully"
„Pain is inevitable; suffering is optional.“
Buddhist proverb
Pain
Chronic and inflammatory pain are significant health issues that necessitate ongoing investment in drug discovery and development. By focusing on innovative and targeted therapies, Pepdura can provide better outcomes for patients suffering from chronic and inflammatory pain, offering hope for improved management and ultimately, a higher quality of life.